Comparative Pharmacology
Head-to-head clinical analysis: DRIXORAL versus PHENETRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRIXORAL versus PHENETRON.
DRIXORAL vs PHENETRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Drixoral is a combination product containing dexbrompheniramine maleate, a first-generation antihistamine that competitively antagonizes histamine at H1 receptor sites, and pseudoephedrine sulfate, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
Phenetron is an antihistamine that competes with histamine for H1-receptor sites, blocking histamine-mediated effects in the respiratory tract, vascular system, and gastrointestinal tract. It also exhibits anticholinergic and sedative properties.
One pseudoephedrine 60 mg and dexbrompheniramine 2 mg tablet orally every 12 hours; maximum 2 tablets per 24 hours.
Adults: 50 mg intramuscularly every 6 hours as needed.
None Documented
None Documented
Dexbrompheniramine: 12-15h (prolonged in renal impairment). Pseudoephedrine: 5-8h (alkaline urine slows elimination, half-life up to 20h).
Terminal half-life 12–15 hours; clinically, steady-state achieved in ~3 days
Drixoral contains dexbrompheniramine (renal: 30-50% unchanged, rest metabolites) and pseudoephedrine (renal: 70-90% unchanged, pH-dependent).
Renal: ~70% unchanged; Biliary/Fecal: ~15% as metabolites; 15% unidentified
Category C
Category C
Antihistamine/Decongestant
Antihistamine